An example is the expression of the Epidermal Growth Factor Receptor (EGFR), and the Vascular Endothelial Growth Factor Receptor (VEGFR) in colorectal cancer, that led to the clinical development of drugs against them, such as panitumumab or cetuximab against EGFR, and bevacizumab against VEGFR [1, 2]. Here, KDR is linked to colorectal cancer.